Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy G Murray

Showing results (241-250 of 260) with videos related to

Pageof 26
Sort By:
Ophthalmology|November 18, 2020
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIERJordi Monés, Sunil K Srivastava, Glenn J Jaffe, et al.
Journal of Vitreoretinal Diseases|August 14, 2020
Occlusive Retinal Vasculitis Following Intravitreal BrolucizumabAndre J Witkin, Paul Hahn, Timothy G Murray, et al.
Journal of Vitreoretinal Diseases|October 4, 2021
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitisAndre J Witkin, Paul Hahn, Timothy G Murray, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 16, 2006
Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3Michele Melia, Claudia S Moy, Sandra M Reynolds, et al.
Retina (Philadelphia, Pa.)|May 12, 2009
Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusionNinel Z Gregori, Jaime Gaitan, Philip J Rosenfeld, et al.
Retina (Philadelphia, Pa.)|July 9, 2009
Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusionNinel Z Gregori, Ginger Henson Rattan, Philip J Rosenfeld, et al.
Ophthalmology|March 24, 2020
The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19Lee M Jampol, Claudia S Moy, Timothy G Murray, et al.
Ophthalmology|December 6, 2002
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19Lee M Jampol, Claudia S Moy, Timothy G Murray, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 11, 2010
Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitisLudimila L Cavalcante, Milena L Cavalcante, Timothy G Murray, et al.
Retina (Philadelphia, Pa.)|August 22, 2009
Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degenerationKimberly E Stepien, Philip J Rosenfeld, Carmen A Puliafito, et al.
Pageof 26

Showing results (241-250 of 260) with videos related to

Sort By:
Pageof 26
Ophthalmology|November 18, 2020
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIERJordi Monés, Sunil K Srivastava, Glenn J Jaffe, et al.
Journal of Vitreoretinal Diseases|August 14, 2020
Occlusive Retinal Vasculitis Following Intravitreal BrolucizumabAndre J Witkin, Paul Hahn, Timothy G Murray, et al.
Journal of Vitreoretinal Diseases|October 4, 2021
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitisAndre J Witkin, Paul Hahn, Timothy G Murray, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 16, 2006
Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3Michele Melia, Claudia S Moy, Sandra M Reynolds, et al.
Retina (Philadelphia, Pa.)|May 12, 2009
Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusionNinel Z Gregori, Jaime Gaitan, Philip J Rosenfeld, et al.
Retina (Philadelphia, Pa.)|July 9, 2009
Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusionNinel Z Gregori, Ginger Henson Rattan, Philip J Rosenfeld, et al.
Ophthalmology|March 24, 2020
The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19Lee M Jampol, Claudia S Moy, Timothy G Murray, et al.
Ophthalmology|December 6, 2002
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19Lee M Jampol, Claudia S Moy, Timothy G Murray, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 11, 2010
Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitisLudimila L Cavalcante, Milena L Cavalcante, Timothy G Murray, et al.
Retina (Philadelphia, Pa.)|August 22, 2009
Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degenerationKimberly E Stepien, Philip J Rosenfeld, Carmen A Puliafito, et al.
Pageof 26